231 related articles for article (PubMed ID: 36435874)
21. Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.
Weiss S; Darvishian F; Tadepalli J; Shapiro R; Golfinos J; Pavlick A; Polsky D; Kirchhoff T; Osman I
BMC Cancer; 2015 Nov; 15():926. PubMed ID: 26597176
[TBL] [Abstract][Full Text] [Related]
22. Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.
Lasocki A; McArthur GA
Melanoma Res; 2022 Oct; 32(5):373-378. PubMed ID: 35979667
[TBL] [Abstract][Full Text] [Related]
23. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
[TBL] [Abstract][Full Text] [Related]
24. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
[TBL] [Abstract][Full Text] [Related]
25. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
26. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
27. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract][Full Text] [Related]
28. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
[TBL] [Abstract][Full Text] [Related]
29. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
Phadke M; Ozgun A; Eroglu Z; Smalley KSM
Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
[TBL] [Abstract][Full Text] [Related]
30. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
31. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
33. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
34. Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.
Azer MW; Menzies AM; Haydu LE; Kefford RF; Long GV
Cancer; 2014 Feb; 120(4):530-6. PubMed ID: 24496868
[TBL] [Abstract][Full Text] [Related]
35. Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Montesinos-Rongen M; Brunn A; Deckert M; Wendl C; Dietmaier W; Goldbrunner R; Ruge MI; Mauch C; Schmidt NO; Proescholdt M; Grau S; Lohmann P
Neuro Oncol; 2022 Aug; 24(8):1331-1340. PubMed ID: 34935978
[TBL] [Abstract][Full Text] [Related]
36. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
37. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ; O'Leary DP; MacNally SP; Kay EW; Farrell MA; Morris PG; Power CP; Hill ADK
Medicine (Baltimore); 2017 Dec; 96(48):e8404. PubMed ID: 29310328
[TBL] [Abstract][Full Text] [Related]
38. Sequence-dependent cross-resistance of combined radiotherapy plus BRAF
Shannan B; Matschke J; Chauvistré H; Vogel F; Klein D; Meier F; Westphal D; Bruns J; Rauschenberg R; Utikal J; Forschner A; Berking C; Terheyden P; Dabrowski E; Gutzmer R; Rafei-Shamsabadi D; Meiss F; Heinzerling L; Zimmer L; Livingstone E; Váraljai R; Hoewner A; Horn S; Klode J; Stuschke M; Scheffler B; Marchetto A; Sannino G; Grünewald TGP; Schadendorf D; Jendrossek V; Roesch A
Eur J Cancer; 2019 Mar; 109():137-153. PubMed ID: 30721788
[TBL] [Abstract][Full Text] [Related]
39. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
40. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
